| Identification | Back Directory | [Name]
Cyclo[3-(2-naphthalenyl)-L-alanylglycyl-3-iodo-D-tyrosyl-N2-methyl-N5-[4-[[[2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]amino]methyl]benzoyl]-D-ornithyl-L-arginyl] | [CAS]
1821136-83-7 | [Synonyms]
Anditixafortide
Cyclo[3-(2-naphthalenyl)-L-alanylglycyl-3-iodo-D-tyrosyl-N2-methyl-N5-[4-[[[2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]amino]methyl]benzoyl]-D-ornithyl-L-arginyl] | [Molecular Formula]
C60H79IN14O14 | [MOL File]
1821136-83-7.mol | [Molecular Weight]
1347.26 |
| Chemical Properties | Back Directory | [density ]
1.52±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted) | [form ]
Solid | [pka]
1.83±0.10(Predicted) | [color ]
White to off-white | [Sequence]
cyclo(Nal-Gly-(3-I-d-Tyr)-(N-Me-Orn(AMBA-DOTA))) |
| Hazard Information | Back Directory | [Uses]
Anditixafortide (Pentixather) is an endoradiotherapeutic vector. Anditixafortide is a CXCR4-targeting peptide derivative[1]. Anditixafortide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs). | [IC 50]
RDC Peptide | [References]
[1] Nicolas Lepareur, et al. Clinical Advances and Perspectives in Targeted Radionuclide Therapy. Pharmaceutics. 223, 15, 6. DOI:10.3390/pharmaceutics15061733
[2] Ken Herrmann, et al. First-in-Human Experience of CXCR4-Directed Endoradiotherapy with 177Lu- and 90Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease. J Nucl Med. 2016, 57, 2. DOI:10.2967/jnumed.115.167361 |
|
| Company Name: |
YantaiBio
|
| Tel: |
13758194781 15083780366 |
| Website: |
|
| Company Name: |
Fuan Bio
|
| Tel: |
18178976185 |
| Website: |
|
|